Showing 3221-3230 of 5972 results for "".
- Allergan, Inc. to Acquire MAP Pharmaceuticals, Inc.https://practicaldermatology.com/news/20130123-allergan_inc_to_acquire_map_pharmaceuticals_inc/2459632/Allergan, Inc. and MAP Pharmaceuticals, Inc. entered into a definitive merger agreement whereby Allergan will acquire 100 percent of the shares of MAP Pharmaceuticals for a price of $25.00 pe
- Viscot Medical Introduces the AllSkin Plus+https://practicaldermatology.com/news/20130110-viscot_medical_introduces_the_allskin_plus/2459644/Viscot Medical released the AllSkin Plus+, a prep resistant ink marker that offers maximum visibility and prep resistance on all skin tones. According to the company, the VIXL brilliant blue ink provides enhanced visibility even after prepping with
- Promius Pharma, LLC Increases Sales Force by 50 Percenthttps://practicaldermatology.com/news/20130102-promius_pharma_llc_increases_sales_force_by_50_percent/2459650/Promius Pharma, LLC is expanding its sales force to 60 from 40. Promius Pharma, which markets clinical prescription products to the US dermatology community, is in growth mode according to Rob D'Urso, head of sales and marketing for the company. “Promius Pharma is gearing up for significant growth
- Perrigo Company Acquires Cobrek Pharmaceuticals, Inc.https://practicaldermatology.com/news/20130102-perrigo_company_acquires_cobrek_pharmaceuticals_inc/2459651/Perrigo Company signed a definitive merger agreement and completed the acquisition of Cobrek Pharmaceuticals, Inc. for approximately $45 million on a cash-free and debt-free basis. The merge concludes a four-year collaborative partnership responsi
- North American Facial Injectable Market to Hit $1.7 Billion by 2017https://practicaldermatology.com/news/20121228-north_american_facial_injectable_market_to_hit_17_billion_by_2017/2459652/According to Millennium Research Group, the North American facial injectables market, comprising botulinum toxin and dermal fillers sold in the US and Canada, will continue to show strong growth for the next five years, reaching a total value of more
- Results Released from Phase 2 Trial of IMO-3100 in Plaque Psoriasishttps://practicaldermatology.com/news/20121219-results_released_from_phase_2_trial_of_imo-3100_in_plaque_psoriasis/2459655/In a recent study, Idera Pharmaceuticals reported that 48 percent of patients with moderate-to-severe plaque psoriasis (12 of 25) treated with IMO-3100, a selective antagonist of Toll-like Receptors (TLRs) 7 and 9, demonstrated improvements in
- Merz, Inc. Acquires ONMEL Oral Treatment for Toenail Fungal Infectionshttps://practicaldermatology.com/news/20121128-merz_inc_acquires_onmel_oral_treatment_for_toenail_fungal_infections/2459671/Merz, Inc. completed the acquisition of ONMEL (itraconazole), an azole antifungal indicated for the oral treatment of onychomycosis of the toenail caused by Trichophyton rubrumor T. Mentagrophytes in non-immunocompromised patients. According to the compa
- Physician Income "Disappointing," But Up Slightlyhttps://practicaldermatology.com/news/20121121-physician_income_disappointing_but_up_slightly/2459674/Although most physicians report that their net income is "disappointing," American physicians saw a slight uptick in income in 2012 compared to 2011, a new report shows. Specialists continue to outpace primary care physicians; 40% of the latter make less than $150,000 per year,
- Asclera's "Stand and Deliver" to Recognize Inspirational Womenhttps://practicaldermatology.com/news/20121101-ascleras_stand_and_deliver_to_recognize_inspirational_women/2459686/Nominations are being accepted through December 31, 2012 for the Stand and Deliver program sponsored by Merz Aesthetics, exclusive distributor of Asclera® (polidocanol) injec
- Suneva Medical Completes Initial Treatment in Phase 3 Acne Scar Studyhttps://practicaldermatology.com/news/20121024-suneva_medical_completes_initial_treatment_in_phase_3_acne_scar_study/2459695/Suneva Medical, Inc. announced that it has completed the enrollment and initial treatment of patients in its Phase 3 acne scar study. This multi-center, prospective study is investigating the efficacy of Artefill for the treatment of moderate to